Anti-Aging Tech Landscape: AI Drug Discovery and Cell Reprogramming Take Center Stage
rand_longevity · x · 2026-08-06
An overview of key players actively working on anti-aging technology and their strategic routes:
- Life Biosciences: Achieved first human dosing of a partial reprogramming therapy, initially targeting ophthalmology.
- BioAge Labs: Completed an IPO and validated its aging-biology data platform through two Big Pharma collaborations.
- NewLimit: Has the fastest capital velocity in epigenetic reprogramming, remaining pre-clinical.
- Retro Biosciences: The best-funded private player in reprogramming, with a clearer path in autophagy than in reprogramming.
- Altos Labs: Launched in 2022 with a record $3B single commitment, but still lacks a disclosed clinical program.
- Insilico Medicine: An AI-native, Asia-anchored platform play, positioning rapid drug discovery speed as its primary edge.
More from Companies & People
- Jeff Dean and Scientists Left Google Citing TPU Infrastructure Limits on Research — firstadopter · 2026-08-06
- Hugging Face Co-founder: Google Could Have Dominated AI by Open-Sourcing Gemini — _akhaliq · 2026-08-06
- Jeff Dean and 3 Google Legends Found AI Startup Discovery Loop — coherence · 2026-08-06
- DeepSeek's 2K-GPU model may beat Google's best, raising questions about GPU efficiency and Google's strategy — teortaxesTex · 2026-08-06
- AI Community Debates: Are Technically Cracked CEOs Crucial for the AGI Era? — JacquesThibs · 2026-08-06
- AI Labs' Vertical Expansion Threatens Legal SaaS and Thin Wrappers — Hacubu · 2026-08-06